Mangoceuticals, Inc. $MGRX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Services-Misc Health & Allied Services, NEC
- Headquarters
- Dallas, TX
- Fiscal year end
- December 31
- Shares outstanding
- 21,567,422 [10-Q 2026-08-13]
What the company doesAI summary of filing
Mangoceuticals, Inc. sells compounded pharmaceutical products through its website via telemedicine consultations. The company's products are compounded by a related-party pharmacy, Epiq Scripts, and distributed directly to customers. The company is currently revenue-generating, selling compounded products for erectile dysfunction (Mango ED), hair loss (Mango GROW), hormone management (Mango MOJO), and weight management (Mango SLIM). Products are prescribed by physicians through the company's telemedicine platform and fulfillment is handled exclusively by Epiq Scripts. [10-K 2026-04-01]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $136.6K | −$4.72M | −$1.57M | $228.7K | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $456.0K | −$20.64M | −$5.85M | $1.49M | [10-K 2026-04-01] |
| FY ended Dec 2024 | $615.9K | −$8.71M | −$4.86M | $58.7K | [10-K 2026-04-01] |
- Quarterly cash burn
- −$785.9K
- Cash runway Estimate
- ~0.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-14 | 2,486,512 | [10-Q 2024-11-14] |
| 2025-03-20 | 5,168,796 | [10-K 2025-03-20] |
| 2025-05-15 | 11,034,023 | [10-Q 2025-05-15] |
| 2025-08-14 | 10,535,791 | [10-Q/A 2025-11-14] |
| 2025-11-13 | 13,906,570 | [10-Q 2025-11-14] |
| 2026-03-31 | 16,967,420 | [10-K 2026-04-01] |
| 2026-05-15 | 17,167,422 | [10-Q 2026-05-19] |
| 2026-08-13 | 21,567,422 | [10-Q 2026-08-13] |
- Shelf registration
- S-1 filed 2026-01-13; declared effective 2026-01-28 [S-1 2026-01-13]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-02-06. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-02-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-06] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-11 | Cohen Jacob D. | other | 2,000,000 | — | [4 2026-10-06] |
| 2026-08-11 | Cohen Jacob D. | other | 2,000,000 | — | [4 2026-10-06] |
| 2026-07-28 | Cohen Jacob D. | grant | 2,000,000 | — | [4 2026-10-06] |
| 2026-07-28 | Johnston Eugene M | grant | 100,000 | — | [4 2026-10-06] |
| 2026-07-28 | Hamilton Alex P. | grant | 100,000 | — | [4 2026-10-06] |
| 2025-12-15 | Johnston Eugene M | sell | 3,333 | $1.17 | [4 2025-12-17] |
| 2025-12-09 | Johnston Eugene M | sell | 5,000 | $1.20 | [4 2025-12-11] |
| 2025-12-05 | Johnston Eugene M | sell | 10,000 | $1.13 | [4 2025-12-09] |
| 2025-09-30 | Cohen Jacob D. | other | 500,000 | — | [4 2026-10-06] |
| 2025-09-30 | Cohen Jacob D. | other | 500,000 | — | [4 2026-10-06] |
| 2025-09-09 | Cohen Jacob D. | grant | 500,000 | — | [4 2026-03-20] |
| 2025-06-05 | Cohen Jacob D. | other | 200,000 | — | [4 2026-03-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Material agreement entered |
| 2026-10-09 | 424B5 | Prospectus or prospectus supplement |
| 2026-10-06 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-10-01 | 8-K | Material agreement entered; Acquisition or disposition completed; Unregistered sale of equity |
| 2026-08-21 | 8-K | Material agreement terminated |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-04 | 8-K | Other events |
| 2026-07-30 | 8-K | Material agreement entered; Director or officer change; Charter, bylaws or fiscal year change |
| 2026-07-02 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-05-19 | 10-Q | Quarterly report |
| 2026-05-15 | NT 10-Q | Notice of late quarterly report |
| 2026-04-01 | 10-K | Annual report |
Alerts for $MGRX
Email me when Mangoceuticals, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.